• Login
    ARAN - Access to Research at NUI Galway
    View Item 
    •   ARAN Home
    • Support Services
    • Externally hosted open access publications with NUI Galway authors (2)
    • View Item
    •   ARAN Home
    • Support Services
    • Externally hosted open access publications with NUI Galway authors (2)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ARANCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypesThis CollectionBy Issue DateAuthorsTitlesSubjectsTypes

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Help

    How to submit and FAQs

    Delivery of strail variants by mscs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects

    Thumbnail
    View/Open
    Full Text
    Date
    2013-02-01
    Author
    Yu, R
    Deedigan, L
    Albarenque, S M
    Mohr, A
    Zwacka, R M
    Metadata
    Show full item record
    Usage
    This item's downloads: 0 (view details)
    Cited 32 times in Scopus (view citations)
    
    Recommended Citation
    Yu, R; Deedigan, L; Albarenque, S M; Mohr, A; Zwacka, R M (2013). Delivery of strail variants by mscs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. Cell Death and Disease 4 ,
    Published Version
    http://www.nature.com/cddis/journal/v4/n2/pdf/cddis201319a.pdf
    Abstract
    Mesenchymal stem cells (MSCs) are able to infiltrate tumor tissues and thereby effectively deliver gene therapeutic payloads. Here, we engineered murine MSCs (mMSCs) to express a secreted form of the TNF-related apoptosis-inducing ligand (TRAIL), which is a potent inducer of apoptosis in tumor cells, and tested these MSCs, termed MSC. sTRAIL, in combination with conventional chemotherapeutic drug treatment in colon cancer models. When we pretreated human colorectal cancer HCT116 cells with low doses of 5-fluorouracil (5-FU) and added MSC. sTRAIL, we found significantly increased apoptosis as compared with single-agent treatment. Moreover, HCT116 xenografts, which were cotreated with 5-FU and systemically delivered MSC. sTRAIL, went into remission. Noteworthy, this effect was protein 53 (p53) independent and was mediated by TRAIL-receptor 2 (TRAIL-R2) upregulation, demonstrating the applicability of this approach in p53-defective tumors. Consequently, when we generated MSCs that secreted TRAIL-R2-specific variants of soluble TRAIL (sTRAIL), we found that such engineered MSCs, labeled MSC.sTRAIL(DR5), had enhanced antitumor activity in combination with 5-FU when compared with MSC. sTRAIL. In contrast, TRAIL-resistant pancreatic carcinoma PancTu1 cells responded better to MSC.sTRAIL(DR4) when the antiapoptotic protein XIAP (X-linked inhibitor of apoptosis protein) was silenced concomitantly. Taken together, our results demonstrate that TRAIL-receptor selective variants can potentially enhance the therapeutic efficacy of MSC-delivered TRAIL as part of individualized and tumor-specific combination treatments. Cell Death and Disease (2013) 4, e503; doi:10.1038/cddis.2013.19; published online 21 February 2013
    URI
    http://hdl.handle.net/10379/14497
    Collections
    • Externally hosted open access publications with NUI Galway authors (2)
    • Copyright @ NUI Galway
    • Library
    • NUI Galway